Shares of Indaptus Therapeutics (INDP) edged up 3.4% to $3.37 on June 26, the first green day after a punishing selloff that shaved roughly 14% off the stock in a week. The trigger: a $12 million private placement with non-U.S. accredited investors announced June 17. For a company with a market cap recently pegged at roughly $3.6 million by one tracker — and 113.24 million shares outstanding — another capital raise lands like a gut punch for existing holders. Here's what matters.
• Another Raise, Same Survival Playbook. Indaptus has tapped investors repeatedly: a $2.1 million direct offering in November 2024 , a $2.25 million placement in January 2025 , $5.7 million in convertible notes by mid-2025 , and a $6 million preferred-stock deal in December 2025 led by David Lazar . The new $12 million raise is the largest yet, but with an accumulated deficit of $83.8 million as of March 31, 2026, and total assets of just $2.2 million , the company is essentially funding operations one placement at a time.
• Dilution Has Already Reshaped the Cap Table. Shareholders voted in February to allow Lazar's preferred stock to convert into 111 million common shares — roughly 96.4% of the fully diluted total. The share count ballooned from about 2.2 million at year-end 2025 to 113.2 million by March 2026 . Each new placement adds more stock to an already flooded pool, diluting every existing shareholder's slice of the pie.
• The Clinical Story Offers Hope, Not Revenue. One patient on the company's lead cancer immunotherapy showed a partial response — shrinking liver tumors — though it didn't last, and early combination-therapy data showed mixed results: one stable case versus two that worsened.
In Q1 2026, the company disclosed it is "reassessing" its platform, development priorities, and resource allocation — hardly a rallying cry.
• A Law Firm Investigation Adds Overhang. On the same day the placement was announced, Abbott Cooper PLLC disclosed it is investigating whether the Indaptus board violated its duties to shareholders in connection with the December 2025 preferred-stock deal. Even if nothing comes of it, the headline risk alone can spook the thin trading volume that defines micro-cap stocks like INDP.
The stock's modest bounce may simply reflect short-sellers covering after a steep drop. With Q1 net losses of $2.5 million , zero revenue, and a management team averaging just 0.3 years of tenure , investors betting on stabilization are really betting that the next catalyst arrives before the next capital raise.